EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, GlycoMimetics's enterprise value is $64.71 Mil.
GlycoMimetics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01 Mil. Therefore, GlycoMimetics's EV-to-Revenue for today is 6,471.40.
The historical rank and industry rank for GlycoMimetics's EV-to-Revenue or its related term are showing as below:
GLYC'
s EV-to-Revenue Range Over the Past 10 Years
Min: -3288.88 Med: 67.37 Max: 29585.49
Current: 6471.4
During the past 13 years, the highest EV-to-Revenue of GlycoMimetics was 29585.49. The lowest was -3288.88. And the median was 67.37.
GLYC's EV-to-Revenue is ranked worse than 98.35% of 1033
companies
in the Biotechnology industry
Industry Median: 7.66
vs GLYC: 6471.40
As of today (2024-04-28), GlycoMimetics's stock price is $1.64.
GlycoMimetics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, GlycoMimetics's PS Ratio for today is .
GlycoMimetics EV-to-Revenue Historical Data
The historical data trend for GlycoMimetics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of GlycoMimetics's EV-to-Revenue
For the Biotechnology subindustry, GlycoMimetics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlycoMimetics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GlycoMimetics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where GlycoMimetics's EV-to-Revenue falls into.
GlycoMimetics's current Enterprise Value is $64.71 Mil.
GlycoMimetics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlycoMimetics's share price for today is $1.64.
GlycoMimetics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlycoMimetics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of GlycoMimetics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
GlycoMimetics (GlycoMimetics) Business Description
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLYC has been successfully added to your 